BioCentury | Jul 9, 2012
Company News

Paladin, Pharmaplan Pty Ltd., Litha Healthcare deal

Paladin completed its acquisition of the 55.01% of drug distributor Pharmaplan it does not already own. Litha then completed its acquisition of 100% of Pharmaplan from Paladin in a stock and cash deal valued at...
BioCentury | Feb 27, 2012
Company News

Paladin, Pharmaplan Pty Ltd., Litha Healthcare deal

Paladin will exercise an option under a 2010 deal to acquire the 55.01% of drug distributor Pharmaplan it does not already own. Litha will then acquire 100% of Pharmaplan from Paladin in a stock and...
BioCentury | May 23, 2011
Clinical News

Rapaflo silodosin: Phase II data

...acquired by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), has co-marketing rights in Italy, and PharmaPlan Pty. Ltd....
BioCentury | Mar 22, 2010
Company News

Paladin, Pharmaplan deal

...deal is part of its strategy to expand internationally. Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Pharmaplan Pty. Ltd....
BioCentury | Feb 8, 2010
Clinical News

Silodyx/Urorec silodosin regulatory update

...Rapaflo in the U.S. Nycomed Group A/S (Zurich, Switzerland) has co-marketing rights in Italy, and PharmaPlan Pty. Ltd....
BioCentury | Nov 23, 2009
Clinical News

Silodyx/Urorec silodosin regulatory update

...Rapaflo in the U.S. Nycomed Group A/S (Zurich, Switzerland) has co-marketing rights in Italy, and PharmaPlan Pty. Ltd....
BioCentury | Aug 3, 2009
Company News

Nycomed Group A/S, PharmaPlan Pty. Ltd., Recordati deal

...with Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan). Nycomed Group A/S , Zurich, Switzerland PharmaPlan Pty. Ltd....
Items per page:
1 - 7 of 7
BioCentury | Jul 9, 2012
Company News

Paladin, Pharmaplan Pty Ltd., Litha Healthcare deal

Paladin completed its acquisition of the 55.01% of drug distributor Pharmaplan it does not already own. Litha then completed its acquisition of 100% of Pharmaplan from Paladin in a stock and cash deal valued at...
BioCentury | Feb 27, 2012
Company News

Paladin, Pharmaplan Pty Ltd., Litha Healthcare deal

Paladin will exercise an option under a 2010 deal to acquire the 55.01% of drug distributor Pharmaplan it does not already own. Litha will then acquire 100% of Pharmaplan from Paladin in a stock and...
BioCentury | May 23, 2011
Clinical News

Rapaflo silodosin: Phase II data

...acquired by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), has co-marketing rights in Italy, and PharmaPlan Pty. Ltd....
BioCentury | Mar 22, 2010
Company News

Paladin, Pharmaplan deal

...deal is part of its strategy to expand internationally. Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Pharmaplan Pty. Ltd....
BioCentury | Feb 8, 2010
Clinical News

Silodyx/Urorec silodosin regulatory update

...Rapaflo in the U.S. Nycomed Group A/S (Zurich, Switzerland) has co-marketing rights in Italy, and PharmaPlan Pty. Ltd....
BioCentury | Nov 23, 2009
Clinical News

Silodyx/Urorec silodosin regulatory update

...Rapaflo in the U.S. Nycomed Group A/S (Zurich, Switzerland) has co-marketing rights in Italy, and PharmaPlan Pty. Ltd....
BioCentury | Aug 3, 2009
Company News

Nycomed Group A/S, PharmaPlan Pty. Ltd., Recordati deal

...with Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan). Nycomed Group A/S , Zurich, Switzerland PharmaPlan Pty. Ltd....
Items per page:
1 - 7 of 7